Syndax Pharmaceuticals' Unattributed Round

Syndax Pharmaceuticals raised a round of funding on November 14, 2013.

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immuno…

Articles about Syndax Pharmaceuticals' Unattributed Round: